Note sull'episodio
By going back to the drawing board, has this global team of founders solved for tricuspid regurgitation, the “forgotten valve”? How far will they advance this breakthrough solution before one of the 4 major cardiovascular giants want to own it?
“Deep Dive” or uncut version of our video podcast. Drs Jeff Brown and Jeff Cole interview Frank Ahmann of Triflo Cardiovascular.
Tricuspid regurgitation (TR) affects millions of elderly patients and is associated with a significant decrease of quality of life, increased hospitalizations, and impaired survival. Symptomatic severe TR is grossly under-treated. The current leading transcatheter technologies only address a limited segment of the patient population.
Southern California - based Triflo Cardiovascular is developing the Tricuspid Flow Optimizer, a minimally invasive valve specifica ...
Parole chiave
private equitycardiovasculartransfemoral valve replacementmedical breakthroughmedical innovation